Aliases:This biomarker is also known as:
- E1A binding protein p300,
- E1A-binding protein, 300kD,
- E1A-associated protein p300,
- p300 HAT,
- histone acetyltransferase p300,
- EC 126.96.36.199,
EP300, or E1A binding protein p300, functions as a histone acetyltransferase and regulates transcription via chromatin remodeling. EP300 is important in the processes of cell proliferation and differentiation, and also functions as acetyltransferase for nonhistone targets. EP300 mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data available.
EP300 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.